Id: acc0007
Group: 1sens
Protein: c-Jun
Gene Symbol: JUN
Protein Id: P05412
Protein Name: JUN_HUMAN
PTM: acetylation
Site: unclear
Site Sequence:
Disease Category: Cancer
Disease: Skin Cancer
Disease Subtype: SCC
Disease Cellline: SCC12
Disease Info:
Drug: ginsenoside Rg3
Drug Info: "Ginsenoside Rg3 is a rare triterpenoid saponin derived from Panax ginseng, clinically utilized as an adjunctive therapeutic agent to enhance chemotherapy efficacy in primary lung and liver cancers by inhibiting tumor angiogenesis, suppressing tumor cell proliferation and metastasis, and improving immune function. "
Effect: modulate
Effect Info: The drug promotes the acetylation of c-Jun to de - inhibit the epithelial - mesenchymal transition of cutaneous squamous cell carcinoma.
Note:
Score: 4.0
Pubmed(PMID): 31192452
Sentence Index:
Sentence:

Sequence & Structure:

MTAKMETTFYDDALNASFLPSESGPYGYSNPKILKQSMTLNLADPVGSLKPHLRAKNSDLLTSPDVGLLKLASPELERLIIQSSNGHITTTPTPTQFLCPKNVTDEQEGFAEGFVRALAELHSQNTLPSVTSAAQPVNGAGMVAPAVASVAGGSGSGGFSASLHSEPPVYANLSNFNPGALSSGGGAPSYGAAGLAFPAQPQQQQQPPHHLPQQMPVQHPRLQALKEEPQTVPEMPGETPPLSPIDMESQERIKAERKRMRNRIAASKCRKRKLERIARLEEKVKTLKAQNSELASTANMLREQVAQLKQKVMNHVNSGCQLMLTQQLQTF

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

JUNB-Lys240
Cancer Intensity
BRCA -1.141
COAD
HGSC
ccRCC
GBM
HNSC
LUAD 0.726
LUSC 0.415
non_ccRCC
PDAC
UCEC
JUNB-Lys284
Cancer Intensity
BRCA -0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC 0.707
non_ccRCC
PDAC
UCEC
JUNB-Lys36
Cancer Intensity
BRCA 0.085
COAD
HGSC
ccRCC
GBM
HNSC
LUAD -1.04
LUSC 0.955
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - D Airway fibrosis Acetylation 34011384
- - P Myeloma Phosphorylation 23175437
- - U Airway fibrosis Acetylation 34011384
- - U Osteogenic sarcoma/osteosarcoma Phosphorylation 24025361

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: